« Previous | Next » | All Messages |  CMED Message Board Home | recommend post |  Ignore Poster

CMED News China Medical Further Expands ECLIA Kit Offering with 10 New Infertility Diagnostic Reagents

BEIJING--(BUSINESS WIRE)--China Medical Technologies, Inc. (the “Company”) (NASDAQ: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic systems and high intensity focused ultrasound products, today announced that it has completed the development of 10 new enhanced chemiluminescence immunoassay (“ECLIA”) infertility diagnostic reagents, increasing the Company’s reagent kit offering to a total of 72. China Medical expects to introduce these new reagents in July 2007.

These reagents are designed to measure a number of different antibodies that affect reproduction and may be used to analyze immunological factors that cause infertility.

The National Population and Family Planning Commission of China estimates that there were over 300 million women of child-bearing age in China in 2006. Approximately 10% of couples in China face infertility problems, which typically refer to situations where couples fail to conceive following two years of attempts. Immunological factors are generally responsible for approximately 30% of infertility problems. Immunological tests provide a way to analyze the possible causes of infertility that arise from the immune system. Timely and accurate diagnosis is a crucial step in determining the appropriate therapy for infertility, where subsequent therapies are made possible to couples planning for pregnancy.

“We are pleased to further expand our reagent kit offering,” stated Mr. Xiaodong Wu, Chairman and CEO of China Medical. “The successful development of these 10 new innovative reagents allows us to offer a more comprehensive portfolio of diagnostic products for infertility disorders that we believe should help improve pregnancy options for couples. With these new kits, along with our Down syndrome and liver fibrosis reagents that we plan to launch in April, we expect our products to reach more user-groups and contribute positively to our financial performance.”

About China Medical Technologies

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostics products using enhanced chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using high intensity focused ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit www.chinameditech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the Company’s expectations with respect to the launching of the above-mentioned reagents and the Company’s expectations that the new reagents may contribute positively to its financial performance contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in China Medical’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. China Medical does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.